Ten-Year Follow-Up in a Case Series of Integrative Botulinum Toxin Intervention in Adolescents with Chronic Daily Headache and Associated Muscle Pain

Abstract

Introduction A total of 83% of children report headache during a 6-month period. The estimated 1-year prevalence of chronic daily headache (CDH) in children is at least 1 to 2%. Muscle pain is associated with headache severity and chronicity. Muscle pain can be associated with active muscular trigger points, a functional concept still remaining a controversy. An integrated approach including bio-behavioral management is accepted as standard treatment but does not provide sufficient pain relief in all patients.

Objective We report the individual clinical course of five adolescents with treatment-refractory CDH associated with focal muscle pain. We describe a concept of short-term integrative intervention including botulinum toxin (StiBo) in a personalized “follow the referred pain pattern” injection regimen with the focus on long-term follow-up.

Results StiBo showed short-term efficacy on headache frequency and severity. In the long-term follow-up, CDH was not existent in any of the patients.

Conclusion The treatment may have enabled the patients to draw attention away from a repeated circle of muscle-triggered pain and withdrawal of daily activities toward self-driven activities, thereby potentially preventing the development of further chronification. To prove this hypothesis, a prospective, placebo-controlled study in young adolescents with CDH should be initiated including objective outcome parameters on muscular level.

Keywords

chronic daily headache - migraine - tension-type headache - muscle pain - botulinum toxin type A - BoNT/A

• References

• 1 Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 (Suppl. 01) 9-160
• 2 Stovner LJ. Headache epidemiology: how and why?. J Headache Pain 2006; 7 (3) 141-144
• 3 Seshia SS. Chronic daily headache in children and adolescents. Curr Pain Headache Rep 2012; 16 (1) 60-72
• 4 Milde-Busch A, Blaschek A, Borggräfe I, von Kries R, Straube A, Heinen F. [Is there an association between the reduced school years in grammar schools and headache and other health complaints in adolescent students?]. Klin Padiatr 2010; 222 (4) 255-260
• 5 Blaschek A, Milde-Busch A, Straube A , et al. Self-reported muscle pain in adolescents with migraine and tension-type headache. Cephalalgia 2012; 32 (3) 241-249
• 6 Berweck S, Schwerin A, Fitzek U, Heinen F. Successful treatment of chronic daily headache by sonography-guided injections of BoNT/A in muscular trigger points. Abstracts of the XI. Congress of the International Headache Society/IHC 2003 Cephalalgia, 2003;23(7):581–762
• 7 Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45 (4) 293-307
• 8 Ahmed K, Oas KH, Mack KJ, Garza I. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol 2010; 43 (5) 316-319
• 9 von Stülpnagel C, Reilich P, Straube A , et al. Myofascial trigger points in children with tension-type headache: a new diagnostic and therapeutic option. J Child Neurol 2009; 24 (4) 406-409
• 10 Simons DG. Symptomatology and clinical pathophysiology of myofascial pain. Schmerz 1991; 5 (Suppl. 01) S29-S37
• 11 Göbel H, Heinze A. [Botulinum toxin type A in the prophylactic treatment of chronic migraine]. Schmerz 2011; 25 (5) 563-570, quiz 571
• 12 Aurora SK, Dodick DW, Turkel CC , et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30 (7) 793-803
• 13 Diener HC, Dodick DW, Aurora SK , et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30 (7) 804-814
• 14 Dodick DW, Turkel CC, DeGryse RE , et al; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50 (6) 921-936
• 15 Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins—an evidence-based review. Pain Med 2011; 12 (11) 1594-1606
• 16 Schulman EA, Lake III AE, Goadsby PJ , et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache 2008; 48 (6) 778-782
• 17 Stewart WF, Lipton RB, Kolodner K. Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 2003; 43 (3) 258-265
• 18 Wang SJ, Fuh JL, Lu SR. Chronic daily headache in adolescents: an 8-year follow-up study. Neurology 2009; 73 (6) 416-422
• 19 Ho KY, Tan KH. Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review. Eur J Pain 2007; 11 (5) 519-527
• 20 Göbel H, Heinze A, Reichel G, Hefter H, Benecke R. Dysport myofascial pain study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 2006; 125 (1-2) 82-88
• 21 Chan VW, McCabe EJ, MacGregor DL. Botox treatment for migraine and chronic daily headache in adolescents. J Neurosci Nurs 2009; 41 (5) 235-243
• 22 Reilich P, Schoser BG. Accuracy of botulinum toxin injections in myofascial pain. Response to Gobel et al. Pain 2006;125:82-8. Pain 2007; 130 (3) 299 , author reply 299–300
• 23 Sikdar S, Shah JP, Gebreab T , et al. Novel applications of ultrasound technology to visualize and characterize myofascial trigger points and surrounding soft tissue. Arch Phys Med Rehabil 2009; 90 (11) 1829-1838
• 24 Schroeder AS, Ertl-Wagner B, Britsch S , et al. Muscle biopsy substantiates long-term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers. Mov Disord 2009; 24 (10) 1494-1503
• 25 Schroeder AS, Koerte I, Berweck S, Ertl-Wagner B, Heinen F. How doctors think—and treat with botulinum toxin. Dev Med Child Neurol 2010; 52 (9) 875-876
• 26 Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache 2005; 45 (3) 232-239